Moderna (MRNA) Stock May Be Fully Priced As Melanoma Vaccine Data Leaks

Moderna has delivered a very large gain over the past year, even after a sharp recent pullback. This puts fresh attention on whether its current share price is supported by the sales investors are effectively paying for. With headlines around vaccine trial data and new product approvals, the question is how much revenue the current valuation already assumes. The stock has risen by roughly 7x over the past 12 months. This raises the question of how much future top line progress the current...